Attached files
| file | filename |
|---|---|
| EX-99.2 - PRESS RELEASE - AzurRx BioPharma, Inc. | ex99-2.htm |
| EX-99.1 - CORPORATE PRESENTATION - AzurRx BioPharma, Inc. | ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): February 12,
2018
AZURRX BIOPHARMA, INC.
(Exact name of Registrant as specified in its Charter)
|
|
|
|
|
Delaware
|
001-37853
|
46-4993860
|
|
(State
or Other Jurisdiction of
Incorporation
or Organization)
|
(Commission
File Number)
|
(I.R.S.
Employer
Identification
No.)
|
|
|
|
|
|
760 Parkside Avenue
Downstate Biotechnology Incubator, Suite 304
Brooklyn, New York
|
11226
|
|
|
(Address
of principal executive
offices)
|
(Zip
Code)
|
|
Registrant’s telephone number, including area code:
(646) 699-7855
(Name,
address, including zip code, and telephone number, including area
code, of agent for service of process)
NOT
APPLICABLE
(Former
Name or Former Address, if Changes Since Last Report)
Check
the appropriate box below if the Form 8-K is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions):
[
] Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
[
] Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
[
] Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
[
] Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (17 CFR
230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17
CFR 240.12b-2) ☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange
Act ☐
Item
7.01
Regulation FD Disclosure
On February 12,
2018, AzurRx BioPharma, Inc. (the “Company”) presented
at the 2018 BIO CEO & Investor Conference in New York City at
the Marriot Marquis, utilizing a new corporate presentation (the
“Corporate Presentation”), a copy of which is attached
as Exhibit 99.1 to this Current Report on Form 8K, and is
incorporated by reference herein.
Item 8.01
Other Events
On
February 12, 2018, the Company issued a press release announcing
its enrollment of three new patients for its phase IIa study of
MS1819 for patients with exocrine pancreatic insufficiency caused
by chronic pancreatitis, which patients were enrolled in sites in
Australia, bringing the total number of patients dosed in the trial
to nine. A copy of the press release is attached hereto as
Exhibit 99.1, and is incorporated by reference herein.
Disclaimer.
The
information in Item 7.01 of this Current Report on Form 8K,
including the information set forth in Exhibit 99.2, is being
furnished and shall not be deemed “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended
(the “Exchange Act”), nor shall it be deemed
incorporated by reference in any filing under the Securities Act of
1933, as amended, or the Exchange Act, except as shall be expressly
set forth by specific reference in such a filing.
Item 9.01
Financial Statements and Exhibits.
See
Exhibit Index.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this Report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
AzurRx BioPharma, Inc.
|
|
Date:
February 12, 2018
|
By:
/s/ Johan M. Spoor
Name: Johan M. Spoor
Title: Chief Executive Officer
|
Exhibit Index
|
Exhibit Number
|
|
Description
|
|
|
|
|
|
|
Corporate Presentation, dated February 2018
|
|
|
|
Press
Release, dated February 12, 2018
|
|
|
|
|
|